Jane Y Wu

US Patent:

8487093, Jul 16, 2013

Filed:

Jan 15, 2009

Appl. No.:

12/812763

Inventors:

Timothy A. Blizzard - Princeton NJ, US
Helen Chen - Marlboro NJ, US
Candido Gude - Staten Island NY, US
Jeffrey D. Hermes - Warren NJ, US
Jason Imbriglio - Piscataway NJ, US
Seongkon Kim - Holmdel NJ, US
Jane Y. Wu - Marlboro NJ, US
Christopher J. Mortko - Hoboken NJ, US
Ian Mangion - Cranford NJ, US
Nelo Rivera - New Milford NJ, US
Rebecca T. Ruck - Jersey City NJ, US
Michael Shevlin - Plainfield NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 243/00
A61K 31/551

US Classification:

540556, 514221

Abstract:

Substituted bicyclic beta-lactams of Formula I: (I), are β-lactamase inhibitors, wherein a, X, Rand Rare defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds can be employed with a β-lactam antibiotics (e. g. , imipenem, piperacillin, or ceftazidime) against microorganisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.

US Patent:

20020165226, Nov 7, 2002

Filed:

Apr 11, 2002

Appl. No.:

10/120723

Inventors:

Frank DiNinno - Old Bridge NJ, US
Jane Wu - Marlboro NJ, US
Seongkon Kim - Holmdel NJ, US
Helen Chen - Livingston NJ, US

International Classification:

C07D279/16
C07D265/36
C07D215/12
A61K031/5415
A61K031/536
A61K031/498
A61K031/47

US Classification:

514/224200, 514/230500, 514/249000, 514/311000, 544/051000, 544/105000, 544/353000, 546/176000

Abstract:

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

US Patent:

20040044226, Mar 4, 2004

Filed:

Apr 15, 2003

Appl. No.:

10/399246

Inventors:

Frank DiNinno - Old Bridge NJ, US
Seongkon Kim - Holmdel NJ, US
Jane Wu - Marlboro NJ, US

International Classification:

C07D335/06
C07D495/02

US Classification:

549/023000, 549/362000

Abstract:

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

US Patent:

20100009957, Jan 14, 2010

Filed:

Sep 24, 2007

Appl. No.:

12/442816

Inventors:

Timothy A. Blizzard - Princeton NJ, US
Helen Y. Chen - Marlboro NJ, US
Jane Yang Wu - Marlboro NJ, US
Seongkon Kim - Holmdel NJ, US
Sookhee Ha - Warren NJ, US
Christopher J. Mortko - Hoboken NJ, US
Narayan Variankaval - Plainsboro NJ, US
Anna Chiu - Redwood City CA, US

International Classification:

A61K 31/397
C07D 205/12
A61P 31/04

US Classification:

51421005, 540203

Abstract:

A class of 7-oxo-2,6-diazabicyclo-[3.2.0]-heptane-6-sulfonic acid compounds substituted at the two position of the bicyclic ring with a heterocyclylaminocarbonyl group or a carbocyclylaminocarbonyl group are β-lactamase inhibitors. The compounds and their prodrugs and pharmaceutically acceptable salts are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds are suitable for use with β-lactam antibiotics (e.g., imipenem and ceftazidime) against micro-organisms resistant to β-lactam antibiotics due to the presence of the β-lactamases.

US Patent:

20180105518, Apr 19, 2018

Filed:

Apr 4, 2016

Appl. No.:

15/562617

Inventors:

- Rahway NJ, US
Yi Heng Chen - Whippany NJ, US
Ping Liu - Westfield NJ, US
Dongfang Meng - Morganville NJ, US
Jane Yang Wu - Marlboro NJ, US
Chun Sing Li - Shanghai, CN
Zhiqi Qi - Shanghai, CN

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/04
C07D 417/12
C07D 487/04
C07D 403/12
A61P 25/00
A61P 35/00
A61P 9/10
A61P 17/06
A61P 7/02

Abstract:

The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I): which are tropomyos-in-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

US Patent:

20180022747, Jan 25, 2018

Filed:

Feb 12, 2016

Appl. No.:

15/550862

Inventors:

Dongfang MENG - Rahway NJ, US
Hong LI - Rahway NJ, US
Meng YANG - Rahway NJ, US
Manuel de Lera RUIZ - West Point PA, US
Sunita V. DEWNANI - Secaucus NJ, US
Tianying JIAN - Rahway NJ, US
Ting ZHANG - Rahway NJ, US
Louis-Charles CAMPEAU - Rahway NJ, US
Bart HARPER - Rahway NJ, US
Harold B. WOOD - Rahway NJ, US
Jiayi XU - Rahway NJ, US
Richard BERGER - West Point PA, US
Jane Yang WU - Rahway NJ, US
Robert K. ORR - Rahway NJ, US
Shawn P. WALSH - Kenilworth NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/04
C07D 403/12
C07D 498/04
C07D 417/14
C07D 513/04
C07D 471/14
C07D 413/14

Abstract:

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

US Patent:

20170114071, Apr 27, 2017

Filed:

Mar 23, 2015

Appl. No.:

15/128689

Inventors:

- Rahway NJ, US
- Shanghai, CN
Andrew J. Cooke - West Point PA, US
Craig A. Stump - West Point PA, US
Casey C. McComas - Phoenixville PA, US
Kathy Schirripa - Quakertown PA, US
Melody McWherter - Boyertown PA, US
Swati P. Mercer - Philadelphia PA, US
Kerim Babaoglu - Lansdale PA, US
Dongfang Meng - Morganville NJ, US
Jane Wu - Marlboro NJ, US
Ping Liu - Westfield NJ, US
Harold B. Wood - Westfield NJ, US
Jianming Bao - Shanghai, CN
Chun Sing Li - Shanghai, CN
Qinghua Mao - Shanghai, CN
Zhiqi Qi - Shanghai, CN

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
MSD R & D (China) Co., LTD. - Shanghai

International Classification:

C07D 491/107
C07D 403/12
C07D 401/12
C07C 233/66
C07D 417/12
C07D 239/42
C07D 401/04
C07D 413/12
C07D 417/14
C07D 401/14
C07D 405/12
C07D 413/14
C07D 403/14
C07D 405/14
C07D 471/04
C07D 401/06
C07D 413/06
C07D 403/06
C07D 213/75

Abstract:

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.